Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Healthy Volunteer
Interventions: DISC-0974, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Placebo-matching telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Mobile, Alabama • Palo Alto, California • San Francisco, California + 13 more

Conditions: Plaque Psoriasis
Interventions: TLL018 tablets; Drug
Lead sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Progressive Supranuclear Palsy
Interventions: Davunetide, Placebo; Drug
Lead sponsor: Allon Therapeutics; Industry
Eligibility: 41 Years to 85 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Obesity
Interventions: Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine; Drug
Lead sponsor: Nastech Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 25 more

Conditions: Obesity, Diabetes Mellitus, Type 2
Interventions: ENT-03, Placebo; Drug
Lead sponsor: Metabolics Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Small Fiber Neuropathy
Interventions: Nicotinamide riboside, Placebo Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Tirzepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Tucson, Arizona • Coronado, California • Pasadena, California + 6 more

Conditions: Alzheimer Disease
Interventions: lecozotan SR (SRA-333); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more

Conditions: Type 2 Diabetes Mellitus
Interventions: ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Anaheim, California + 15 more

Conditions: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions: Bupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Systemic Lupus Erythematosus
Interventions: Ortho-Novum 777; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more

Conditions: Acne
Interventions: Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,001 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more

Conditions: Diabetic Retinopathy, Low Vision
Interventions: Eye4, Placebo; Device · Other
Lead sponsor: Eyedaptic; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Acute Kidney Injury
Interventions: Oral niacinamide, 1 gram daily, Oral niacinamide, 3 gram daily, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Soluble Fiber, Placebo; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Allergic Rhinitis
Interventions: Nasaleze Spray, Placebo spray, Allergen; Drug · Other · Biological
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Creatine monohydrate or placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type I Diabetes
Interventions: NNC0361-0041, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Pneumonia
Interventions: chlorhexidine gluconate oral rinse (0.12%), placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Charcot-Marie-Tooth Disease Type 1A
Interventions: PXT3003 dose 1, PXT3003 dose 2, placebo; Drug
Lead sponsor: Pharnext S.C.A.; Other
Eligibility: 16 Years to 65 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • New Britain, Connecticut • Gainesville, Florida + 8 more

Conditions: Asthma
Interventions: Atuliflapon, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 64
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 52 more

Conditions: Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
Interventions: Nicotinamide riboside; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 35 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Adult Form of Celiac Disease
Interventions: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

Safety of Estrogens in Lupus: Birth Control Pills

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury

Meta-analysis of Soluble Fiber Consumption on Body Weight, Glycemia, and Insulinemia in Overweight and Obese Adults.

Effect of Nasaleze on Nasal Challenge With Allergen

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients